{"filing":{"accession_number":"0001193125-26-331563","cik":"0001829802","ticker":"SNSE","company_name":"Faeth Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"d168633d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526331563/d168633d8k.htm"},"events":[{"id":23867,"run_id":21588,"accession_number":"0001193125-26-331563","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026), filed under Item 2.02 as a press release exhibit. The disclosure includes condensed statements of operations, balance sheet data, R\u0026D and G\u0026A expenses, net loss per share, and cash position—all hallmarks of an earnings release. While the filing also mentions operational updates (clinical trial progress, executive appointments, name change), the core Item 2.02 disclosure is the quarterly financial results announcement.","company_name":"Faeth Therapeutics, Inc.","ticker":"SNSE","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24218,"accession_number":"0001193125-26-331563","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026), filed under Item 2.02 as a press release exhibit. The disclosure includes condensed statements of operations, balance sheet data, R\u0026D and G\u0026A expenses, net loss per share, and cash position—all hallmarks of an earnings release. While the filing also mentions operational updates (clinical trial progress, executive appointments, name change), the core Item 2.02 disclosure is the quarterly financial results announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:42.727801+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24218,"accession_number":"0001193125-26-331563","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026), filed under Item 2.02 as a press release exhibit. The disclosure includes condensed statements of operations, balance sheet data, R\u0026D and G\u0026A expenses, net loss per share, and cash position—all hallmarks of an earnings release. While the filing also mentions operational updates (clinical trial progress, executive appointments, name change), the core Item 2.02 disclosure is the quarterly financial results announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:42.727801+00:00","company_name":"Faeth Therapeutics, Inc.","ticker":"SNSE","filing_date":"2026-08-04"}]}